	Sep 2025	Jun 2025	Sep 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	3.07	20.15	41.34	-84.8%	-92.6%
Operating Profit Qtr	-4.00	-0.50	0.79	-700.0%	-606.3%
Net Profit Qtr	-6.25	-21.12	-3.23	70.4%	-93.5%
Earning Per Share Adjusted latest Qtr	-1.25	-4.22	-0.64	70.4%	-95.3%

* Standalone data

Detailed Results

Lasa Supergenerics Ltd.

14 Nov 2025

9.42

-1.36%

Board Meeting

Lasa Supergenerics Ltd - 540702 - Board Meeting Outcome for Outcome Of Board Meeting For The …

BSE India

Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 2.30 P.M. and concluded at 05.00 P.M. inter- alia have considered and approved the following: 1. The Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025. 2. Limited Review Report from Statutory Auditor for the quarter and half year ended on September 30, 2025.

pdf

Lasa Supergenerics Ltd.

10 Nov 2025

9.42

-1.36%

Board Meeting

Lasa Supergenerics Ltd - 540702 - Update on board meeting

BSE India

The Board Meeting to be held on 14/11/2025 has been revised to 14/11/2025 The Board Meeting to be held on 14/11/2025 has been revised to 14/11/2025

pdf

Lasa Supergenerics Ltd.

05 Nov 2025

9.42

-1.36%

Board Meeting

Lasa Supergenerics Ltd - 540702 - Board Meeting Intimation for The Quarter And Half Year Ended …

BSE India

Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Friday, August 14, 2025, inter alia; 1. To consider, approve and take on records Unaudited financial results of the Company for the quarter and half year ended September 30, 2025. 2. To discuss any other matter with the permission of the Chairperson. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Conduct, the Trading Window shall continue to remain closed till 48 hours after the declaration of the unaudited financial results of the Company for the quarter and half year ended September 30, 2025.

pdf

Lasa Supergenerics Ltd.

14 Oct 2025

9.42

-1.36%

Company Update

Lasa Supergenerics Ltd - 540702 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Please find enclosed herewith certificate of 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended September, 30 2025 received from RTA Bigshare Services Private Limited

pdf

Lasa Supergenerics Ltd.

01 Oct 2025, 07:47PM

9.42

-1.36%

AGM

Lasa Supergenerics Ltd - 540702 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

BSE India

In terms of the subject referred the details regarding consolidated voting results of the business transacted at the 10th Annual General Meeting (AGM) of the company held on Tuesday 30th September 2025

pdf

Lasa Supergenerics Ltd.

30 Sep 2025, 04:14PM

9.42

-1.36%

AGM

Lasa Supergenerics Ltd - 540702 - Shareholder Meeting / Postal Ballot-Outcome of AGM

BSE India

Pursuant to Reg 30 SEBI (LODR), 2015 as amended we hereby submitting the summary of the proceedings of the 10 th AGM of the Company held on 30th September, 2025 at 11.00 AM and Concluded at 11.20 through video conferencing.

pdf

Lasa Supergenerics Ltd.

29 Sep 2025

9.42

-1.36%

SAST

Lasa Supergenerics Ltd - 540702 - Closure of Trading Window

BSE India

This is to inform you that as per the Company''s Code for Regulating, Monitoring and Reporting of Trading by the Insiders in terms of (prohibition of Insider trading )Regulations 2015, the trading window for dealing in equity shares of the Company has been closed for designated emplouees and their immediate relative w.e.f 1st october, 2025 till 48 hours after declaration of unaudited financial results for the quarter ended September 30, 2025

pdf

Is Lasa Supergenerics Ltd. worth buying?

54 Votes:

Buy 77.78%

Sell 16.67%

Hold 5.56%